MRD Analytical Validation Working Group

Jimmy Lin, MD, PhD

Chief Scientific Officer

Freenome

Co-Chairs

Mark Sausen, PhD

Senior Director, Precision Medicine Search, Evaluation & Alliances

Bristol Myers Squibb

Current Projects

MRD Tumor-Agnostic AV Protocols (manuscript in preparation)

Participating Organizations

Adela, Association for Molecular Pathology (AMP), AstraZeneca, Bristol Myers Squibb (BMS), Delfi Diagnostics, Exact Sciences, Foundation Medicine, Freenome, Grail, Guardant Health, Horizon Discovery, Illumina, Labcorp, LGC SeraCare, Memorial Sloan Kettering Cancer Center (MSKCC), Meridian Life Sciences, Natera, NeoGenomics, Pfizer, Roche Diagnostics, Tempus, Ultima Genomics, Veracyte

Past Deliverables

January 2026: Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation

Meetings

This working group meets on zoom every other Thursday from 3:30 PM - 5:00 PM EST.

Special workshops and sessions:

Not applicable at this time.